Draft. Pending scientific and legal review. Not medical advice.
Next-generation sequencing (NGS)
Next-generation sequencing (NGS) can study many genes or nearly the whole genome in one assay. The catalogue describes exome, whole genome and high-coverage panels, including structural variants and CNV detection when the method supports it. Broad sequencing can generate unsolicited findings.
Study types
In the catalogue, the NGS sequencing line includes:
- Clinical exome (WES): coding regions of most genes. - Exome with a mitochondrial component (WES-MT), when listed on the sheet. - Whole genome (WGS): broader sequencing, useful for certain variants not covered by the exome.
Thematic NGS panels (neurology, cardiology, oncology and others) are described in their clinical areas; this page explains the shared methodological frame.
Exome versus genome
The exome focuses on protein-coding DNA. The genome includes non-coding regions and may improve detection of certain structural variants, depending on the pipeline. Neither guarantees detecting every possible genetic cause.
For a patient-oriented explanation, see the guide «Difference between exome and genome». Choosing exome, genome or panel is set by the professional according to the clinical suspicion.
Thematic panels versus broad sequencing
A thematic NGS panel focuses reading on genes selected for a clinical axis (neurology, cardiology, oncology, infertility and so on). It can be more efficient when suspicion is bounded. An exome or genome widens the search when the phenotype is complex or prior panels have not answered the question.
No approach guarantees a positive result. A negative result reduces, but does not eliminate, the chance of a genetic cause detectable with the technology used. Laboratory-stated sensitivity, once available after Phase 0, should appear on the technical sheet, not as a promise on this page.
Unsolicited findings and consent
Broad sequencing can generate unsolicited findings. Which categories are returned, and whether the person wants to know them, is recorded in consent before the test. This site does not collect that choice.
ACMG recommendations on secondary-finding genes and ESHG guidance provide an ethical and technical frame; concrete application is set by the laboratory and the responsible clinician.
Pending
Pending Phase 0: stated coverage and sensitivity, turnaround, sample type and a sample report. Until then this page publishes no analytical performance figures.
